TACSTD2 and lung carcinoma: Preclinical studies demonstrated robust in vitro cytotoxicity of PF-06664178 against Trop2-positive tumor cell lines and promising in vivo antitumor efficacy in a range of PDX models, including TNBC, ovarian, and lung cancers 31.